A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib

This report presents a unique case of a vitiligo patient with concomitant systemic lupus erythematosus. Remarkably, after a 30-day course of treatment with tofacitinib, complete repigmentation of the white macular rash was achieved, and there were no adverse drug reactions. These findings provide compelling evidence for the efficacy and safety of oral JAK inhibitors, such as tofacitinib, in vitiligo treatment. Additionally, JAK inhibitors can yet be regarded as a promising new treatment option for vitiligo patients with concurrent autoimmune diseases.PMID:38524393 | PMC:PMC10961069 | DOI:10.2147/CCID.S448535
Source: Clinical, Cosmetic and Investigational Dermatology - Category: Dermatology Authors: Source Type: research